曲洛单抗治疗成人中重度特应性皮炎。

Q1 Medicine Skin therapy letter Pub Date : 2023-01-01

Abrahim Abduelmula, Brian D Rankin, Asfandyar Mufti, Jensen Yeung, Vimal H Prajapati

{"title":"曲洛单抗治疗成人中重度特应性皮炎。","authors":"Abrahim Abduelmula, Brian D Rankin, Asfandyar Mufti, Jensen Yeung, Vimal H Prajapati","doi":"","DOIUrl":null,"url":null,"abstract":"Atopic dermatitis (AD) is a common, chronic, recurrent, immune-mediated inflammatory skin disease. Targeted treatment options remain limited. Tralokinumab (Adtralza®) is a promising, new systemic therapy that inhibits interleukin-13. It was recently approved by Health Canada and the US FDA for the treatment of moderate-to-severe AD in adults and may be used alone or with topical corticosteroids. Herein, we review the efficacy and safety of tralokinumab in adults, as demonstrated in clinical trials.","PeriodicalId":21829,"journal":{"name":"Skin therapy letter","volume":"28 1","pages":"1-6"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Tralokinumab for Moderate-to-Severe Atopic Dermatitis in Adults.\",\"authors\":\"Abrahim Abduelmula, Brian D Rankin, Asfandyar Mufti, Jensen Yeung, Vimal H Prajapati\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Atopic dermatitis (AD) is a common, chronic, recurrent, immune-mediated inflammatory skin disease. Targeted treatment options remain limited. Tralokinumab (Adtralza®) is a promising, new systemic therapy that inhibits interleukin-13. It was recently approved by Health Canada and the US FDA for the treatment of moderate-to-severe AD in adults and may be used alone or with topical corticosteroids. Herein, we review the efficacy and safety of tralokinumab in adults, as demonstrated in clinical trials.\",\"PeriodicalId\":21829,\"journal\":{\"name\":\"Skin therapy letter\",\"volume\":\"28 1\",\"pages\":\"1-6\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Skin therapy letter\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Skin therapy letter","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

特应性皮炎(AD)是一种常见的慢性、复发性、免疫介导的炎症性皮肤病。有针对性的治疗方案仍然有限。Tralokinumab (Adtralza®)是一种有前景的新型全身疗法，可抑制白细胞介素-13。它最近被加拿大卫生部和美国FDA批准用于成人中度至重度AD的治疗，可单独使用或与局部皮质类固醇一起使用。在此，我们回顾了临床试验证明的曲洛单抗在成人中的有效性和安全性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Tralokinumab for Moderate-to-Severe Atopic Dermatitis in Adults.

Atopic dermatitis (AD) is a common, chronic, recurrent, immune-mediated inflammatory skin disease. Targeted treatment options remain limited. Tralokinumab (Adtralza®) is a promising, new systemic therapy that inhibits interleukin-13. It was recently approved by Health Canada and the US FDA for the treatment of moderate-to-severe AD in adults and may be used alone or with topical corticosteroids. Herein, we review the efficacy and safety of tralokinumab in adults, as demonstrated in clinical trials.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊